Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pounding the table on $NBIO, low floater, about to pop. Have a powerful day fellas!!!
NBIO massive bid, nothing on the ask. I few tags and she runs. Lets go!
Its ready, just needs a push. Moves on air. Real company 2 drugs in the pipeline, one with FDA grant for human trials.
$NBIO Lets get this low floater moving.
$NBIO Nascent Biotech Inc. .19!!!
2 Cancer Drugs
Human trials
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
5,600,000 Float
Clean Level 2
No convertibles
Moves on air
Under the radar....not for long, This is going to have an epic run. This is the bottom.
$NBIO Nascent Biotech Inc. .19!!!
2 Cancer Drugs
Human trials
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
5,600,000 Float
Clean Level 2
No convertibles
Moves on air
This is the most under the radar pick. Any awareness and it explodes.
$NBIO Nascent Biotech Inc. .19!!!
2 Cancer Drugs
Human trials
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
5,600,000 Float
Clean Level 2
No convertibles
Moves on air
Keep an eye on $NBIO, super thin moves on air, cancer drug in human trials. 5,600,000 Float!!!
NBIO SECURITY DETAILS
Share Structure
Market Cap
6,202,861
05/20/2019
Authorized Shares
100,000,000
05/15/2019
Outstanding Shares
32,646,635
05/15/2019
Restricted
22,589,220
05/15/2019
Unrestricted
10,057,415
05/15/2019
Held at DTC
5,861,867
05/15/2019
Float
5,667,867
11/12/2018
Par Value
0.00
Add $NBIO to this list!!! Keep an eye on $NBIO, super thin moves on air, cancer drug in human trials.
NBIO SECURITY DETAILS
Share Structure
Market Cap
6,202,861
05/20/2019
Authorized Shares
100,000,000
05/15/2019
Outstanding Shares
32,646,635
05/15/2019
Restricted
22,589,220
05/15/2019
Unrestricted
10,057,415
05/15/2019
Held at DTC
5,861,867
05/15/2019
Float
5,667,867
11/12/2018
Par Value
0.00
Keep an eye on $NBIO, super thin moves on air, cancer drug in human trials.
NBIO SECURITY DETAILS
Share Structure
Market Cap
6,202,861
05/20/2019
Authorized Shares
100,000,000
05/15/2019
Outstanding Shares
32,646,635
05/15/2019
Restricted
22,589,220
05/15/2019
Unrestricted
10,057,415
05/15/2019
Held at DTC
5,861,867
05/15/2019
Float
5,667,867
11/12/2018
Par Value
0.00
This is primed and ready for a massive run.
Keep an eye on $NBIO, super thin moves on air, cancer drug in human trials.
Keep an eye on $NBIO, super thin moves on air, cancer drug in human trials.
Keep an eye on $NBIO, super thin moves on air, cancer drug in human trials.
Roll your profits into $NBIO. Calm before the storm, cancer drug in human trials.
Roll your profits into $NBIO. Calm before the storm, cancer drug in human trials.
NBIO ***Alert*** $NBIO ***Pounding The Table***$NBIO
2 Cancer Drugs
Human trials in process
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
5,600,000 Float
Clean Level 2
No convertibles
Moves on air
$5.00 by end of the year buy out target.
NBIO ***Alert*** $NBIO ***Pounding The Table***$NBIO
2 Cancer Drugs
Human trials in process
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
5,600,000 Float
Clean Level 2
No convertibles
Moves on air
$5.00 by end of the year buy out target.
$NBIO paper thin no dilution.
NBIO SECURITY DETAILS
Share Structure
Market Cap
4,896,995
04/29/2019
Authorized Shares
100,000,000
04/24/2019
Outstanding Shares
32,646,635
04/24/2019
Restricted
22,589,220
04/24/2019
Unrestricted
10,057,415
04/24/2019
Held at DTC
5,861,867
04/24/2019
Float
5,667,867
11/12/2018
Par Value
0.00
$NBIO is about to take off again. Great pipeline, real company, trades on AIR....
$NBIO round 2 about to start here fellas. ding ding ding
super thin, drug pipeline robust!!
$NBIO round 2 about to start here fellas. ding ding ding
super thin, drug pipeline robust!!
$NBIO about to take off super thin, massive drug pipeline.
$NBIO about to take off super thin, massive drug pipeline.
$NBIO round 2 coming ding ding ding. Most under the radar pick available. Massive opportunity.
$NBIO round 2 coming ding ding ding. Most under the radar pick available. Massive opportunity.
$NBIO about to run hard again. Right back to .77 trades super thin.
$NBIO ready again!!!
$NBIO under the radar for now.
DIS one of the best value plays available. Ripping today.
$NBIO .55 time is running short. It is going to explode soon. Mark it.
$NBIO Nascent Biotech Inc. ***POUNDING THE TABLE HERE FELLAS***
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing
$NBIO Nascent Biotech Inc. ***POUNDING THE TABLE HERE FELLAS***
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing
$NBIO Could be the next screamer...Check it out...
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO ***Alert*** Nascent Biotech Inc. ***Alert***
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO Nascent Biotech Inc.
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
$NBIO ***Alert*** Nascent Biotech Inc. ***Alert***
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
Clean Level 2
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.
WOWZER those NFLX 380 C went from .09 to 8.60.... Dear lord. What a bounce. I love being on the sidelines....not.
$NBIO $NBIO $NBIO Nascent Biotech Inc.
2 Cancer Drugs
Human trials coming
No debt
No dilution
OTCQB Fully Reporting
Transparent TA
8,000,000 Float
No convertibles
Moves on air
$NBIO Share Structure:
Outstanding Shares
28,543,295
07/03/2018
Restricted
20,133,185
07/03/2018
Float
8,410,110
07/03/2018
Nascent Biotech Significant Milestones Achieved since 2015
Re-engineered antibody into CHO cells: The original cell line was created as a Hybridoma. Manufacturing from the Hybridoma cell line was a prohibitively expensive very process. A recombinant form was created that secretes over 40 fold more antibodies.
Created and fully characterized and qualified Master Cell Bank (MCB):
Produced 400+ grams of GMP grade mAb: This is a key inflection point with Biotech Investors which mitigates manufacturing risk. Formulation studies show that the antibodies are stable.
Pre-IND and clinical protocol discussions with FDA: There were no preclinical issues and the FDA provided guidance for our Study Protocol which increases the probability that we will gain IND approval on the first attempt. This also mitigates IND trial delays.
Settled $1.7M debt to license holder
Retired debenture – eliminating 30% shareholder dilution.
Finished in life phase toxicology studies (monkey and rat): “This is the easiest study I have ever seen. I wish all my Toxicology Studies went this well,” Fred Reno-Toxicology trial consultant. Completing the toxicology study mitigates toxicology issues. Nascent had none.
Completed Viral Clearance study – Significantly exceeds FDA recommendations.
Completed Fill and Finish of purified bulk product.
Filed IND Application April 2017 – Finalizing FDA requested studies. Plan to refile by mid Q 1 2018 (FDA requested a new Viral Clearance Study and a Tox/Clinical lot Comparative Analysis).
Signed $16 Million licensing deal with Hisun Pharmaceuticals for Mainland China - $ 3 million received in upfront payment – Saved investors significant dilution.
Raised $1.45 Million in equity investment – no debt financing.